Literature DB >> 21552935

Induction of tumorigenicity by galectin-3 in a nontumorigenic human breast-carcinoma cell-line.

P Nangiamakker1, E Thompson, C Hogan, J Ochieng, A Raz.   

Abstract

The human galectin-3 is a galactoside-binding protein of 31 kDa which functions as a receptor for glycoproteins containing poly N-acetyllactosamine side chains and as a substrate for matrix metalloproteinases-2 and -9. We studied its expression by flow cytoflourimetry, Western, Northern and Southern analyses, in five cultured human breast carcinoma cell lines previously characterized as nontumorigenic, poorly metastatic or metastatic in nude mice. The expression of galectin-3 correlated with the reported tumorigenicity of the cells. The introduction of recombinant galectin-3 into the null expressing non-tumorigenic BT-549 cells resulted in the acquisition of anchorage-independent growth properties in all and tumorigenicity in 3/4 sense transfected cell clones. The data indicate a relationship between galectin-3 expression and malignancy of human breast carcinoma cell lines.

Entities:  

Year:  1995        PMID: 21552935     DOI: 10.3892/ijo.7.5.1079

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  18 in total

Review 1.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

2.  Galectin-3 induces endothelial cell morphogenesis and angiogenesis.

Authors:  P Nangia-Makker; Y Honjo; R Sarvis; S Akahani; V Hogan; K J Pienta; A Raz
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of β-catenin in gastric cancer.

Authors:  Seok-Jun Kim; Ji-Young Shin; Teak-Chin Cheong; Il-Ju Choi; Yeon Su Lee; Seok Hee Park; Kyung-Hee Chun
Journal:  Clin Exp Metastasis       Date:  2011-07-13       Impact factor: 5.150

4.  Lectin, galactoside-binding, soluble, 3 rs4652 A/C gene variation and the risk for rheumatoid arthritis.

Authors:  Mahdi Atabaki; Mohammad Hashemi; Hamid Daneshvar; Ebrahim Alijani
Journal:  Biomed Rep       Date:  2017-01-09

5.  Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Ann G Schwartz; Young Suk Jung; Larry Tait; Victor Hogan; Tirza Raz; Yi Wang; Zeng Quan Yang; Gen Sheng Wu; Yongjun Guo; Huixiang Li; Judith Abrams; Fergus J Couch; Wilma L Lingle; Ricardo V Lloyd; Stephen P Ethier; Michael A Tainsky; Avraham Raz
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

6.  Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions.

Authors:  Malathy P V Shekhar; Pratima Nangia-Makker; Larry Tait; Fred Miller; Avraham Raz
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

7.  Regulation of prostate cancer progression by galectin-3.

Authors:  Yi Wang; Pratima Nangia-Makker; Larry Tait; Vitaly Balan; Victor Hogan; Kenneth J Pienta; Avraham Raz
Journal:  Am J Pathol       Date:  2009-03-12       Impact factor: 4.307

8.  The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop.

Authors:  Selvi Ramasamy; Sekhar Duraisamy; Sergei Barbashov; Takeshi Kawano; Surender Kharbanda; Donald Kufe
Journal:  Mol Cell       Date:  2007-09-21       Impact factor: 17.970

9.  Inhibition of galectin-3 mediated cellular interactions by pectic polysaccharides from dietary sources.

Authors:  U V Sathisha; Smitha Jayaram; M A Harish Nayaka; Shylaja M Dharmesh
Journal:  Glycoconj J       Date:  2007-05-25       Impact factor: 2.916

10.  Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers.

Authors:  Pratima Nangia-Makker; Tirza Raz; Larry Tait; Victor Hogan; Rafael Fridman; Avraham Raz
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.